FDA Follow-on Proteins Draft Guidance Will Be Followed By Third Public Meeting
This article was originally published in The Pink Sheet Daily
Executive Summary
The agency's next step on "generic" biologics is to release a background document on FDA's past regulatory and scientific treatment of protein products. The draft guidance – which could be a set of "interlocking" guidances – will be released subsequent to the background document.